Peripheral Neuropathy Treatment Market, by Indication, by Treatment (Pharmacological Therapies and Non-pharmacological Therapies, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Peripheral neuropathy is a disorder of the peripheral nerves. These nerves send messages between the central nervous system, the brain and the spinal cord, and the rest of the body. Peripheral neuropathy can result from traumatic injuries, infections, metabolic problems, inherited causes, and exposure to toxins. One of the most common causes is diabetes. Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. Individual with peripheral neuropathy generally describe the pain as stabbing, burning or tingling. In many cases, symptoms improve, especially if caused by a treatable condition. Medications such as Lyrica, Cymbalta, etc can reduce the pain of peripheral neuropathy.

Market Dynamics

Key players operating in the global peripheral neuropathy treatment market are focusing on adoption growth strategies such as product launch, and approval which are expected to drive the market growth during the forecast period. For instance, in July 2019, Alembic Pharmaceuticals Limited, an Indian pharmaceutical company, announced that it received the approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pregabalin Capsules that is used for peripheral neuropathic pain. Moreover, various government agencies focusing on investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy which is expected to drive the market growth over forecast period. For instance, in November 2018, the U.S. National Cancer Institute awarded/invested US$ 2.3 Mn in Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs.

Key features of the study:

• This report provides an in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global peripheral neuropathy treatment market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy's Laboratories Ltd, Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., and NeuroBo Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.

Detailed Segmentation:

• Global Peripheral Neuropathy Treatment Market, By Indication :
• Diabetic Peripheral Neuropathy
• Chemotherapy-induced Peripheral Neuropathy
• Idiopathic Peripheral Neuropathy
• Others
• Global Peripheral Neuropathy Treatment Market, By Treatment :
• Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
• Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
• Global Peripheral Neuropathy Treatment Market, By End User :
• Hospital
• Ambulatory Centers
• Others
• Global Peripheral Neuropathy Treatment Market, By Region:

• North America
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange

o

• Others
• By End User
• Hospital
• Ambulatory Centers
• Others
• By Country
• U.S.
• Canada
• Latin America
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others

o

• By End User
• Hospital
• Ambulatory Centers
• Other
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Abbott Laboratories*
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Johnson & Johnson
• Dr. Reddy's Laboratories Ltd
• Pfizer, Inc.
• Cipla Inc.
• Lupin Limited
• Averitas Pharma, Inc.
• NeuroBo Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.